DB1099Z
Brachytherapy Trachea to None with Iodine 125 (I-125), High Dose Rate (HDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | B Respiratory System |
| Operation | 1 Brachytherapy |
| Body Part | 0 Trachea |
| Approach | 9 High Dose Rate (HDR) |
| Device | 9 Iodine 125 (I-125) |
| Qualifier | Z None |
Procedure Overview
Brachytherapy of the respiratory system places a radioactive source directly inside or immediately next to lung or airway tissue, most often through a bronchoscope that guides a catheter to the tumor site. This lets clinicians deliver a concentrated dose to a small area, such as a tumor growing into the bronchus and narrowing the airway, while sparing surrounding lung tissue that an external beam would have to pass through.
It is frequently used to relieve breathing difficulty caused by an obstructing endobronchial tumor, and it can also serve as a targeted boost after a course of external beam treatment. The radioactive source may be left in place temporarily during a single procedure or, less commonly, implanted for a longer period.
Anatomy & Axis Detail
Trachea
The trachea is the central airway connecting the larynx to the mainstem bronchi, and brachytherapy here involves placing a radioactive source, typically via bronchoscopically guided catheter, directly within or adjacent to the airway lumen to treat endotracheal tumors or recurrent disease after external radiation. This intraluminal approach delivers a highly concentrated dose to the airway wall while sparing surrounding mediastinal structures, making it useful for relieving airway obstruction and controlling local tumor growth even when further external beam treatment is not feasible. Because the source sits temporarily within the airway during treatment, careful catheter positioning and airway stabilization are essential, and documentation should specify tracheal placement to distinguish it from bronchial applications performed further downstream.
Modality Qualifier: High Dose Rate (HDR)
High Dose Rate (HDR) identifies brachytherapy delivered with a radioactive source of high activity, allowing treatment to be completed in minutes per fraction, often on an outpatient basis with afterloading applicators. It contrasts with Low Dose Rate (LDR), which uses a weaker source left in place for hours to days, trading a longer treatment time for a different radiobiological effect and staffing exposure profile.
Isotope: Iodine 125 (I-125)
Iodine-125 is a low-energy, low-dose-rate radioisotope most often loaded into small permanent seeds implanted directly into tissue, commonly for early-stage prostate cancer or ocular tumors via plaque brachytherapy. Its longer half-life (about 60 days) gives a slower, more protracted dose delivery than Pd-103 or Cs-131, which is the key distinction among the permanent-seed isotopes.
Coding & Documentation
Coding this family depends on documentation confirming that a radioactive source was placed within or adjacent to respiratory tissue, including the specific structure treated, the isotope or source type, and whether the implant was temporary or intended to remain in place. The procedure note from the bronchoscopy or interventional session is the key source document. A common mistake is coding the catheter or applicator placement itself as a separate Medical and Surgical procedure when it was performed solely to deliver the radiation, rather than recognizing it as part of the brachytherapy episode. Coders also sometimes miss the qualifier distinguishing a temporary source from a permanent one.
Commonly Confused With
The main point of confusion is with beam radiation, since both treat similar tumors - the distinction is strictly whether the radiation source is inserted into the body or delivered from an external device. It can also be confused with a diagnostic or therapeutic bronchoscopy performed for other reasons; if the bronchoscope is used purely as the delivery route for a radioactive source, the encounter is coded as brachytherapy rather than as a separate endoscopic procedure.